Iza‑Bren is an experimental cancer medicine being studied for people with advanced cancers, including certain types of lung cancer and nasopharyngeal cancer. It is not yet approved for routine use and is currently available only through clinical trials.
Iza-Bren belongs to a newer class of treatments called antibody–drug conjugates (ADCs). These medicines are designed to deliver chemotherapy directly to cancer cells rather than exposing the whole body to high levels of chemotherapy.
What Types Of Cancer Is Iza-Bren Being Studied For?
Iza-Bren is mainly being studied in people with cancers that involve two proteins called EGFR and HER3, which help cancer cells grow and survive. These cancers include:
- Non–small cell lung cancer (NSCLC), especially cancers with EGFR mutations
- Nasopharyngeal carcinoma, a cancer that develops behind the nose
- Other advanced solid tumors that have stopped responding to standard treatments
Many patients enrolled in Iza-Bren studies have already received chemotherapy, targeted therapy, or both.
Read About FDA Breakthrough Therapy Designation for Iza-bren on OncoDaily
How Does Iza-Bren Work?
Iza-Bren works like a guided delivery system.
It has two main parts:
- A targeting antibody that recognizes EGFR and HER3 on cancer cells
- A chemotherapy payload attached to the antibody
The antibody finds and attaches to cancer cells that carry EGFR or HER3. Once attached, Iza-Bren is taken inside the cancer cell, where it releases the chemotherapy directly into the cell. This helps kill the cancer cell from the inside while reducing exposure to healthy cells. This approach is sometimes described as a “smart chemotherapy” strategy.
Why Are EGFR And HER3 Important?
EGFR and HER3 are proteins found on the surface of some cancer cells. They send signals that tell cancer cells to grow and divide.
In many cancers—especially lung cancer—treatments that block EGFR work well at first but stop working over time. One reason is that HER3 can help cancer cells bypass EGFR-blocking treatments. By targeting both EGFR and HER3 at the same time, Iza-Bren is designed to overcome this escape mechanism and continue attacking the cancer.
What Have Clinical Studies Shown So Far?
Early and mid-stage clinical trials have shown promising results, even in patients who had already tried multiple treatments.
In studies of patients with advanced lung cancer:
- More than half of patients saw their tumors shrink
- Cancer control lasted several months or longer in many patients
In a large study of patients with nasopharyngeal cancer, Iza-Bren worked better than standard chemotherapy in shrinking tumors and delaying cancer growth. Because of these encouraging results, the U.S. Food and Drug Administration (FDA) granted Iza-Bren a special status called Breakthrough Therapy Designation for certain lung cancer patients. This status helps speed up further research and review.
Read About Phase III Trial Results on OncoDaily
What Side Effects Have Been Reported?
Like all cancer treatments, Iza-Bren can cause side effects. The most common side effects seen in studies so far include:
- Low white blood cell counts
- Fatigue
- Nausea
- Anemia (low red blood cells)
Doctors closely monitor patients during treatment and adjust doses if needed. Importantly, serious lung inflammation—a concern with some lung cancer treatments—has not been a major issue so far, though monitoring continues.
Because Iza-Bren is still being studied, doctors are carefully collecting safety information to better understand both short- and long-term side effects.
How Is Iza-Bren Given?
Iza-Bren is given through a vein (intravenous infusion) at a hospital or cancer center. Treatment is usually given every few weeks, depending on the study.
Patients are monitored before, during, and after treatment to ensure safety and manage side effects.
Is Iza-Bren Approved?
No. Iza-Bren is still an investigational treatment.
It can only be received by participating in a clinical trial. Larger studies are ongoing to confirm how well it works and whether it helps patients live longer.
Should Patients Consider A Clinical Trial?
Clinical trials offer access to promising new treatments before they are widely available. They also include close medical monitoring and follow strict safety rules. If you have advanced cancer and standard treatments are no longer working, your doctor may discuss whether a clinical trial involving Iza-Bren could be an option for you.
What Comes Next For Iza-Bren?
Researchers are continuing to study Iza-Bren in different cancers and treatment settings, including combinations with other targeted therapies. Future studies will help determine:
- Which patients benefit the most
- How long responses last
- Where Iza-Bren fits best in cancer treatment plans
While more research is needed, Iza-Bren represents an important step forward in precision cancer therapy, aiming to treat cancer more effectively while reducing harm to healthy cells.
You Can Watch More on OncoDaily Youtube TV
Written by Armen Gevorgyan, MD